PureTech (PRTC) Presents Additional Phase 1 Data for LYT-100

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to PureTech (PRTC) Presents Additional Phase 1 Data for LYT-100

PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022

May 16, 2022 9:30 AM EDT

Further data from Phase 1 study in healthy older adults demonstrate improved tolerability profile of LYT-100 compared to pirfenidone

Data support the planned LYT-100 dose-ranging registration-enabling studies in idiopathic pulmonary fibrosis, with topline results expected in 2023

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage... More